Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avobenzone/Zinc/Phenylbenzimidazole Sunscreen Efficacy Data Needed - FDA

This article was originally published in The Tan Sheet

Executive Summary

Additional efficacy data are needed before FDA can approve the use of avobenzone with zinc oxide and phenylbenzimidazole sulfonic acid in OTC sunscreens, the agency tells Procter & Gamble in a Sept. 15 letter.

You may also be interested in...



P&G Avobenzone Combo Data Demonstrate Broad Spectrum Protection - FDA

The combinations of avobenzone and either zinc oxide or phenylbenzimidazole sulfonic acid (PBSA) are safe and effective for use in sunscreens "when used in the concentrations established for each ingredient" in the sunscreen final monograph, FDA tells Procter & Gamble in a Nov. 2 letter.

P&G Avobenzone Combo Data Demonstrate Broad Spectrum Protection - FDA

The combinations of avobenzone and either zinc oxide or phenylbenzimidazole sulfonic acid (PBSA) are safe and effective for use in sunscreens "when used in the concentrations established for each ingredient" in the sunscreen final monograph, FDA tells Procter & Gamble in a Nov. 2 letter.

P&G Avobenzone Combo Data Demonstrate Broad Spectrum Protection - FDA

The combinations of avobenzone and either zinc oxide or phenylbenzimidazole sulfonic acid (PBSA) are safe and effective for use in sunscreens "when used in the concentrations established for each ingredient" in the sunscreen final monograph, FDA tells Procter & Gamble in a Nov. 2 letter.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS088915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel